Orthofix (NASDAQ: OFIX) posts Q1 2026 growth, narrows loss and maintains 2026 goals

Rhea-AI Filing Summary

Orthofix Medical Inc. reported first-quarter 2026 results that show modest growth and improved bottom-line performance while reaffirming its full-year outlook. Reported net sales were $196.7 million, up 1.6% year over year, with non-GAAP pro forma net sales of $196.4 million, up 2.7% on a constant currency basis as spine distributor transitions tapered off.

Global Spine Fixation grew 6% and Therapeutic Solutions grew 5% year over year on a constant currency basis, while Global Limb Reconstruction net sales rose 3%. GAAP net loss narrowed to $20.9 million, or $(0.52) per share, compared with a net loss of $53.1 million, or $(1.35) per share, a year earlier.

Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales, versus $11.4 million, or 6.0%, reflecting geography mix and commercial transitions. Cash, cash equivalents, and restricted cash increased to $120.9 million as of March 31, 2026, helped by financing activities, while free cash flow was negative $28.3 million. The company reaffirmed 2026 guidance for net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive full-year free cash flow excluding any potential legal settlements.

Insights

Medical technology equity analyst

Orthofix posts modest Q1 growth, narrower loss, and keeps its 2026 outlook intact.

Orthofix delivered Q1 2026 net sales of $196.7 million, up 1.6% year over year, with pro forma constant currency growth of 2.7%. Segment trends were mixed but generally positive: Global Spine Fixation grew 6%, Therapeutic Solutions grew 5%, and Global Limb Reconstruction grew 3%, indicating stable demand across core franchises.

Profitability remains constrained. GAAP net loss narrowed to $20.9 million, but non-GAAP pro forma adjusted EBITDA slipped to $9.7 million (4.9% margin) from $11.4 million (6.0% margin), reflecting geography mix and ongoing commercial transitions. Non-GAAP pro forma adjusted gross margin of 70.7% improved modestly versus 70.3% a year ago, suggesting early traction from efficiency efforts.

Liquidity strengthened, with cash, cash equivalents, and restricted cash at $120.9 million as of March 31, 2026, up from $85.1 million at year-end, driven by financing flows. Management reaffirmed full-year 2026 guidance for net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow excluding potential legal settlements, tying its outlook to improved commercial execution and margin initiatives through 2026.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q1 2026 reported net sales: $196.7 million Q1 2026 pro forma net sales: $196.4 million Q1 2026 GAAP net loss: $20.9 million +5 more

8 metrics

Q1 2026 reported net sales $196.7 million Up 1.6% year over year; includes M6 product sales

Q1 2026 pro forma net sales $196.4 million Up 2.7% year over year on a constant currency basis

Q1 2026 GAAP net loss $20.9 million Improved from $53.1 million net loss in Q1 2025

Q1 2026 adjusted EBITDA (pro forma) $9.7 million 4.9% of pro forma net sales vs $11.4 million and 6.0% in Q1 2025

Q1 2026 adjusted gross margin (pro forma) 70.7% Non-GAAP pro forma; up from 70.3% in Q1 2025

Cash, cash equivalents, and restricted cash $120.9 million As of March 31, 2026; up from $85.1 million at December 31, 2025

2026 net sales guidance $850–$860 million Implied ~5.5% year-over-year pro forma constant currency growth at midpoint

2026 adjusted EBITDA guidance $95–$98 million Targets 70 bps adjusted EBITDA margin expansion vs 2025

Key Terms

non-GAAP pro forma adjusted EBITDA, constant currency, free cash flow, Adjusted Gross Margin, +2 more

6 terms

non-GAAP pro forma adjusted EBITDA financial

"Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales"

constant currency financial

"non-GAAP pro forma net sales were $196.4 million, excluding sales from M6 discs, representing an increase of 1.6% on a reported basis and 2.7% on a non-GAAP pro forma constant currency basis"

Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.

free cash flow financial

"Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow provided by or used in operating activities"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

Adjusted Gross Margin financial

"Adjusted gross margin as a percentage of pro forma net sales | | | 70.7 | %"

Adjusted gross margin is a measure of how much profit a company makes from its sales after accounting for certain expenses or one-time costs, but before deducting other operating expenses. It helps investors see the company's core profitability more clearly by removing factors that might distort the usual profit picture, similar to a runner measuring their speed without considering obstacles or weather. This metric provides a clearer view of the company's ongoing financial health.

Employee retention credit financial

"Employee retention credit - Pertains to refunds received, interest earned, or professional fees incurred associated with the refundable payroll tax credit"

A government-provided payroll tax credit that reimburses employers for a portion of wages paid to staff during qualifying downturns or disruptions, designed to encourage businesses to keep employees on the payroll. For investors, it matters because the credit improves a company’s cash flow and reduces payroll expenses—like a temporary government subsidy that boosts short-term profits and may change the company’s reported tax liabilities and cash reserves, which can affect valuation and risk assessments.

Acquisition-related fair value adjustments financial

"Acquisition-related fair value adjustments – Comprised of (i) gains and losses related to remeasurement of contingent consideration to fair value"

Earnings Snapshot

Net sales: $196.7 million · Guidance included

Q1 2026

Net sales $196.7 million +1.6% year over year reported

Pro forma net sales $196.4 million +2.7% year over year constant currency

GAAP net loss $20.9 million improved from $53.1 million loss in Q1 2025

Adjusted EBITDA (pro forma) $9.7 million down from $11.4 million in Q1 2025

Adjusted gross margin (pro forma) 70.7% up from 70.3% in Q1 2025

Free cash flow -$28.3 million slightly more negative than -$25.1 million in Q1 2025

Guidance

For full-year 2026, Orthofix guides to net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow excluding any potential legal settlements.

Understanding 8-K Material Events →

0000884624false00008846242026-05-052026-05-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 05, 2026

ORTHOFIX MEDICAL INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			000-19961	98-1340767
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3451 Plano Parkway
Lewisville, Texas				75056
(Address of Principal Executive Offices)				(Zip Code)

Registrant's Telephone Number, Including Area Code: (214) 937-2000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.10 par value per share		OFIX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 5, 2026, Orthofix Medical Inc. (the "Company") issued a press release announcing, among other things, its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto.

The information furnished in this Item 2.02, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 2.02 of this report.

Discussion of Non-GAAP Financial Measures

In addition to using standard measures of performance and liquidity that are recognized in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company uses additional financial measures excluding certain GAAP items ("non-GAAP measures"), such as:

Constant Currency

Constant currency is a non-GAAP measure, which the Company calculates by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

Free Cash Flow

Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow provided by or used in operating activities. Free cash flow is an important indicator of how much cash is generated or used by the Company's business operations, including capital expenditures. Management uses free cash flow to measure progress on its capital efficiency and cash flow initiatives.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted gross profit represents GAAP gross profit with adjustments to exclude the impact of the certain items recorded to cost of goods sold. Potential adjustments are listed within the section below under the header "Non-GAAP Adjustments." Adjusted gross margin represents adjusted gross profit as a percentage of GAAP net sales.

Adjusted Net Income (Loss)

Adjusted net income (loss) represents GAAP net loss with adjustments to exclude the impact of certain items recorded in such GAAP net loss. Potential adjustments are listed within the section below under the header "Non-GAAP Adjustments."

Adjusted Operating Expenses

Adjusted operating expenses represents GAAP operating expenses, such as sales, general, and administrative expense, and research and development expense, with adjustments to exclude the impact of certain items recorded in such GAAP operating expenses. Potential adjustments are listed within the section below under the header "Non-GAAP Adjustments."

Adjusted Non-Operating Expenses

Adjusted non-operating expenses represents GAAP non-operating expenses, such as interest income (expense), net and other income (expense), net, with adjustments to exclude the impact of certain items recorded in such GAAP non-operating expenses. Potential adjustments are listed within the section below under the header "Non-GAAP Adjustments."

EBITDA

EBITDA is a non-GAAP financial measure, which the Company calculates by adding interest expense (income), net; income tax expense (benefit); and depreciation and amortization to net income (loss). EBITDA provides management with additional insight into the Company's results of operations. Adjusted EBITDA, which is the primary metric used by the Company's chief operating decision maker in managing the business, consists of EBITDA with adjustments to exclude certain items listed within the section below under the header "Non-GAAP Adjustments."

Non-GAAP Adjustments

The Company's non-GAAP financial measures provide management with additional insight into the Company's results of operations and reflect the exclusion of the following items:

•Share-based compensation and long-term incentive plan expense – Costs related to awards granted under the Company's share-based compensation plans, which include stock options, performance-based or market-based stock options, restricted stock units, performance-based or market-based restricted stock units, stock issued under the Company's stock purchase plan, and performance-based cash-settled awards; see the share-based compensation footnote in the Company's Form 10-Q for the quarter ended March 31, 2026, for an allocation of share-based compensation costs by consolidated

statement of operations line item. Management excludes this item when evaluating the Company's operating performance as it primarily represents a non-cash expense.

•Foreign exchange impact – Gains and losses related to foreign currency transactions, which are recorded as other income (expense), net. Management excludes this item when evaluating the Company's operating results as it is primarily a non-cash expense or benefit and is non-operating in nature.

•SeaSpine merger-related costs – Costs related to the Company's merger with SeaSpine Holdings Corporation ("SeaSpine"), which was consummated in January 2023, including costs relating to integration efforts, severance and retention costs, product rationalization charges, contract termination penalties, and professional fees related to the merger. Management excludes this item when evaluating the Company's operating results as these costs associated with this event are of a temporary nature, are not related to the Company's core operating performance, and are not expected to recur at a similar frequency and magnitude in the future.

•Strategic investments – Costs related to the Company's strategic investments, such as due diligence and integration costs (unrelated to the merger with SeaSpine), which are primarily recorded as sales, general, and administrative expenses. These costs are not factored into the evaluation of the Company's performance by management because they are of a temporary nature, not related to the Company's core operating performance, and because the frequency and amount of such costs vary significantly based on the timing and magnitude of the Company's strategic investments.

•Acquisition-related fair value adjustments – Comprised of (i) gains and losses related to remeasurement of contingent consideration to fair value, which are recorded as operating expenses, (ii) recognized costs related to acquired in-process research and development ("IPR&D") assets, which are expensed immediately, and (iii) amortization of acquired inventory fair market value adjustments. Management excludes these adjustments when evaluating the Company's operating results as (i) the remeasurement of contingent consideration is primarily non-cash in nature, (ii) the frequency and amount of IPR&D charges can vary significantly based on the timing and magnitude of the Company's acquisition transactions, and (iii) inventory fair market value adjustments are of a temporary and non-cash nature.

•Amortization/depreciation of acquired long-lived assets – Amortization of intangible assets acquired in business combinations or asset acquisitions, including items such as developed technologies, customer relationships, trade names, manufacturing agreements, and other intangible assets, and any impairment of acquired goodwill, which are recorded in cost of sales or operating expenses. This item also includes depreciation recognized on adjustments to the fair value of certain long-lived assets acquired in the merger with SeaSpine. Management excludes this item when evaluating the Company's operating performance as it represents a non-cash expense.

•Interest and gain (loss) on investments – Interest income and net gains or losses recognized (realized or unrealized) within interest income (expense), net and other income (expense), net, respectively, relating to certain of the Company's investments. Management excludes these items when evaluating the Company's operating performance as it typically represents a non-cash gain or loss and is not related to the Company's core operating performance.

•Litigation and investigation-related costs – Inclusive of (i) adverse or favorable legal judgments or negotiated legal settlements and certain related legal expenses and (ii) amounts incurred in relation to and as a result of the Board of Directors' investigation conducted by independent outside legal counsel that resulted in the departure of three former executive officers and certain charges stemming from these actions. These charges are primarily recorded within sales, general, and administrative expenses. Management excludes these items when evaluating the Company's operating results as these costs and/or benefits can vary significantly based on the timing, frequency, and magnitude of litigation matters or investigations.

•Restructuring costs and impairments related to M6 product lines - Restructuring costs, including severance-related benefits, and impairment charges incurred as a result of the Company's decision to discontinue its M6 artificial disc product lines. Management excludes this item when evaluating the Company's operating results as these costs associated with this event are one-time in nature and are not related to the Company's expected ongoing operations.

•Employee retention credit - Pertains to refunds received, interest earned, or professional fees incurred associated with the refundable payroll tax credit established by the Coronavirus Aid, Relief, and Economic Security Act. Management excludes this item when evaluating the Company's operating results as these amounts primarily relate to costs incurred in prior years, and are not related to the Company's ongoing operations.

•Long-term income tax rate adjustment – Reflects management's expectation of a long-term normalized effective tax rate of 28% for 2025 and 2026 results, which is based on current tax law and current expected adjusted income; actual reported tax expense will ultimately be based on GAAP earnings and may differ from the expected long-term normalized effective tax rate due to a variety of factors, including the resolution of issues arising from tax audits with various tax authorities, the ability to realize deferred tax assets, and the tax impact of certain reconciling items that are excluded in determining adjusted net income (loss).

Usefulness and Limitations of Non-GAAP Financial Measures

Management uses non-GAAP measures to evaluate performance period-over-period, analyze the underlying trends in the Company's business, assess the Company's performance relative to its competitors, and establish operational goals and forecasts used in allocating resources. Management uses these non-GAAP measures as the basis for evaluating the ability of the Company's underlying operations to generate cash, prior to required investments in working capital, and to further its understanding of the performance of the Company's business units.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

The non-GAAP financial measures described above may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost and can have a material effect on cash flows. Similarly, certain non-cash expenses, such as share-based compensation, do not directly impact cash flows, but are part of total compensation costs accounted for under GAAP.

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

The Company compensates for the limitations of its non-GAAP financial measures by relying upon GAAP results to gain a complete picture of the Company's performance. GAAP results provide management with the ability to understand the Company's performance based on a defined set of criteria. The Company provides reconciliations of the non-GAAP financial measures to the most directly comparable GAAP measures and encourages investors to review these reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that providing non-GAAP financial measures, which exclude certain items, offers investors greater transparency into the information used by management in its financial and operational decision-making. Management believes it is important to provide investors with the same non-GAAP financial measures it uses to supplement information regarding the performance and underlying trends of the Company's business operations in order to facilitate comparisons to the Company's historical operating results and internally evaluate the effectiveness of the Company's operating strategies. The Company believes that these non-GAAP financial measures also facilitates comparisons of the Company's underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

Item 7.01 Regulation FD Disclosure.

The Company expects to use the corporate investor relations presentation furnished as Exhibit 99.2 to this report, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others during the fiscal year ending December 31, 2026.

The information furnished in this Item 7.01, including the exhibit furnished herewith as Exhibit 99.2, will not be treated as "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act, or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	Press release, dated May 5, 2026
99.2	Corporate Investor Relations Presentation, dated May 5, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Orthofix Medical Inc.
By:		/s/ JULIE ANDREWS
		Julie Andrews Chief Financial Officer

Date: May 5, 2026

Exhibit 99.1

News Release

Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine

Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

LEWISVILLE, Texas — May 5, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ product lines.

Highlights

•First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a constant currency basis, reflecting steady execution during the final stages of distributor transitions, with further improvement expected as productivity increases.

•Global Spine Fixation1 delivered reported net sales growth of 6% and constant currency growth of 6% compared to the prior year period, including U.S. Spine Fixation growth of 4%, driven by enhanced commercial focus, deeper procedural penetration, and continuing benefits from distributor transition initiatives.

•Therapeutic Solutions (formerly Bone Growth Therapies) achieved year-over-year net sales growth of 5%, supported by continued demand across the portfolio and effective commercial execution.

•Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems.

•First quarter 2026 reported net loss of $(20.9) million and non-GAAP pro forma adjusted EBITDA of $9.7 million, reflecting impacts from geography mix and commercial transitions.

“Our first-quarter results reflect steady execution as we complete key spine commercial channel actions and sharpen our strategic focus,” said Massimo Calafiore, President and Chief Executive Officer. “While the quarter continued to absorb the impact of these transitions, most notably in biologics, we saw improved commercial focus and operating discipline as the quarter progressed.”

Mr. Calafiore continued, “Importantly, distributor transitions are now largely behind us, providing greater visibility for the remainder of the year. As we move through 2026, our priorities are clear: driving more consistent commercial execution, advancing targeted innovation across our portfolio, and expanding margins through disciplined operational management. With recent spine leadership changes, a renewed focus on advancing our biologics portfolio, and planned product launches later this year, we believe Orthofix is positioned to deliver more consistent growth, expand margins, and generate strong free cash flow to support long-term shareholder value.”

1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings.

1

Financial Results Overview

First Quarter 2026 Net Sales and Financial Results

The following table provides net sales by major product category and by reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines:

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in millions)		2026				2025				Change				Constant Currency Change
Therapeutic Solutions		$	57.8			$	55.1				4.9	%			4.9	%
Spinal Implants, Biologics and Enabling Technologies*			105.8				104.3				1.4	%			1.4	%
Global Spine*			163.6				159.4				2.6	%			2.6	%
Global Limb Reconstruction			32.8				29.8				10.2	%			3.0	%
Pro forma net sales*			196.4				189.2				3.8	%			2.7	%
Impact from discontinuation of M6 product lines			0.3				4.4				(94.2	%)			(94.5	%)
Reported net sales		$	196.7			$	193.6				1.6	%			0.4	%

* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.

For the first quarter of 2026, net sales were $196.7 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales were $196.4 million, excluding sales from M6 discs, representing an increase of 1.6% on a reported basis and 2.7% on a non-GAAP pro forma constant currency basis compared to first quarter 2025.

For the first quarter of 2026, GAAP gross margins were 70.9% and were 70.7% on a non-GAAP pro forma adjusted basis.

For the first quarter of 2026, reported net loss was $(20.9) million, or $(0.52) per share compared to reported net loss of $(53.1) million, or $(1.35) per share in the prior year period. Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales, in the first quarter of 2026, compared to non-GAAP pro forma adjusted EBITDA of $11.4 million, or 6.0% of pro forma net sales, in the first quarter of 2025.

Liquidity

Cash, cash equivalents, and restricted cash on March 31, 2026, totaled $120.9 million compared to $85.1 million on December 31, 2025. The cash increase was a result of financing activities during the quarter.

Business Outlook

Based on first-quarter performance and current visibility, the Company is reaffirming its full-year 2026 financial guidance. This outlook reflects expectations for improved execution through the remainder of the year, including contributions from recent and planned product launches, balanced against ongoing macro and operational considerations.

•Net sales expected to range between $850 million to $860 million. The Company’s expected net sales represent implied year-over-year pro forma constant currency growth of approximately 5.5% at the midpoint of the range. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year.

•Non-GAAP adjusted EBITDA expected to be $95 million to $98 million. This represents 70 basis points of non-GAAP adjusted EBITDA margin expansion at the midpoint of the range compared to 2025.

•Free cash flow expected to be positive for full-year 2026, excluding the impact of any potential legal settlements, supported by margin improvement initiatives.

An investor presentation for the Company’s first quarter 2026 financial results is available in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com.

2

Conference Call

Orthofix will host a conference call today at 8:30 AM Eastern time to discuss the Company’s financial results for the first quarter ended March 31, 2026. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast and replay of the conference call may be accessed in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com.

Internet Posting of Information

Orthofix regularly shares important updates in the “Investors” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.

About Orthofix

Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company delivers technology-enabled solutions that support improved clinical outcomes and more efficient care across the continuum. Orthofix offers a focused and differentiated portfolio spanning spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Learn more at Orthofix.com and follow Orthofix on LinkedIn.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “positioned,” “deliver,” or “continue” or other comparable terminology. Forward-looking statements in this communication include the Company’s expectations regarding net sales, adjusted EBITDA, and free cash flow for the year ended December 31, 2026. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to successfully optimize our commercial channels, (vii) our success in defending legal proceedings brought against us, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. The Company undertakes no obligation to update, and expressly disclaims any duty to update, its forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law.

The Company is unable to provide expectations of GAAP net income (loss), the closest comparable GAAP measures to adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP.

3

Company Contact

Investors and Media

Julie Dewey, IRC

Chief Investor Relations & Communications Officer

JulieDewey@Orthofix.com

+1 209.613.6945

4

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Operations

		Three Months Ended
		March 31,
(Unaudited, U.S. Dollars, in thousands, except share and per share data)		2026				2025
Net sales		$	196,708			$	193,646
Cost of sales			57,162				72,027
Gross profit			139,546				121,619
Sales, general, and administrative			134,911				132,981
Research and development			15,320				19,766
Acquisition-related amortization, impairment, and remeasurement			3,751				17,745
Operating loss			(14,436	)			(48,873	)
Interest expense, net			(5,664	)			(4,506	)
Other income (expense), net			(734	)			1,246
Loss before income taxes			(20,834	)			(52,133	)
Income tax expense			(74	)			(961	)
Net loss		$	(20,908	)		$	(53,094	)
Net loss per common share:
Basic		$	(0.52	)		$	(1.35	)
Diluted			(0.52	)			(1.35	)
Weighted average number of common shares (in millions):
Basic			40.4				39.2
Diluted			40.4				39.2

5

ORTHOFIX MEDICAL INC.

Condensed Consolidated Balance Sheets

(U.S. Dollars, in thousands, except par value data)		March 31, 2026				December 31, 2025
		(Unaudited)
Assets
Current assets
Cash and cash equivalents		$	120,278			$	82,025
Restricted Cash			592				3,090
Accounts receivable, net of allowances of $8,990 and $8,308, respectively			137,775				135,746
Inventories			177,818				172,319
Prepaid expenses and other current assets			25,057				23,667
Total current assets			461,520				416,847
Property, plant, and equipment, net			125,327				129,399
Intangible assets, net			69,336				72,765
Goodwill			194,934				194,934
Other long-term assets			35,484				36,702
Total assets		$	886,601			$	850,647
Liabilities and shareholders’ equity
Current liabilities
Accounts payable		$	54,686			$	58,392
Current portion of finance lease liability			115				837
Other current liabilities			106,232				111,253
Total current liabilities			161,033				170,482
Long-term debt			221,335				157,391
Long-term portion of finance lease liability			12,937				17,060
Other long-term liabilities			56,110				55,677
Total liabilities			451,415				400,610
Contingencies
Shareholders’ equity
Common shares $0.10 par value; 100,000 shares authorized;     40,382 and 39,834 issued and outstanding as of March 31,     2026, and December 31, 2025, respectively			4,038				3,983
Additional paid-in capital			820,247				813,769
Accumulated deficit			(389,241	)			(368,333	)
Accumulated other comprehensive income			142				618
Total shareholders’ equity			435,186				450,037
Total liabilities and shareholders’ equity		$	886,601			$	850,647

6

ORTHOFIX MEDICAL INC. Non-GAAP Financial Measures

The following tables present reconciliations of various financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to various non-GAAP financial measures that exclude (or in the case of free cash flow, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s current report on Form 8-K regarding this press release filed today with the SEC available on the SEC’s website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com.

The Company’s non-GAAP financial measures for the three months ended March 31, 2026, and 2025, have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6 product lines.

Adjusted Gross Profit and Adjusted Gross Margin

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Gross profit		$	139,546			$	121,619
Share-based compensation and long-term incentive plan expense			331				461
SeaSpine merger-related costs			(528	)			600
Restructuring costs and impairments related to M6 product lines			(437	)			10,919
Strategic investments			—				13
Amortization/depreciation of acquired long-lived assets			177				313
Adjusted gross profit		$	139,089			$	133,925
Adjusted gross margin as a percentage of reported net sales			70.7	%			69.2	%
Adjusted gross profit attributable to M6 product lines			(242	)			(906	)
Pro forma adjusted gross profit		$	138,847			$	133,019
Pro forma adjusted gross margin as a percentage of pro forma net sales			70.7	%			70.3	%

Adjusted EBITDA

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Net loss		$	(20,908	)		$	(53,094	)
Income tax expense			74				961
Interest expense, net			5,664				4,506
Depreciation and amortization			13,493				34,431
Share-based compensation and long-term incentive plan expense			6,638				6,469
Foreign exchange impact			900				(1,044	)
SeaSpine merger-related costs			(69	)			1,130
Restructuring costs and impairments related to M6 product lines			(437	)			9,880
Strategic investments			950				3,514
Acquisition-related fair value adjustments			750				(610	)
Interest and (gain) loss on investments			(16	)			—
Litigation and investigation costs			2,916				3,042
Employee retention credit			(951	)			—
Adjusted EBITDA		$	9,004			$	9,185
Adjusted EBITDA as a percentage of reported net sales			4.6	%			4.7	%
Operating losses attributable to M6 product lines			690				2,246
Pro forma adjusted EBITDA		$	9,694			$	11,431
Pro forma adjusted EBITDA as a percentage of pro forma net sales			4.9	%			6.0	%

7

Adjusted Net Income (Loss)

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Net loss		$	(20,908	)		$	(53,094	)
Share-based compensation and long-term incentive plan expense			6,638				6,469
Foreign exchange impact			900				(1,044	)
SeaSpine merger-related costs			17				1,474
Restructuring costs and impairments related to M6 product lines			(624	)			30,204
Strategic investments			953				3,543
Acquisition-related fair value adjustments			750				(610	)
Amortization/depreciation of acquired long-lived assets			3,178				4,632
Litigation and investigation costs			2,916				3,042
Interest and (gain) loss on investments			(16	)			—
Employee retention credit			(1,135	)			—
Long-term income tax rate adjustment			2,106				2,200
Adjusted net loss		$	(5,225	)		$	(3,184	)
Operating losses attributable to M6 product lines			916				2,688
Long-term income tax rate adjustment for M6 product lines			(256	)			(753	)
Pro forma adjusted net loss		$	(4,565	)		$	(1,249	)

Cash Flow and Free Cash Flow

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Net cash used in operating activities		$	(17,610	)		$	(18,391	)
Net cash used in investing activities			(10,515	)			(6,736	)
Net cash provided by (used in) financing activities			63,970				(651	)
Effect of exchange rate changes on cash			(90	)			493
Net change in cash and cash equivalents		$	35,755			$	(25,285	)

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Net cash used in operating activities		$	(17,610	)		$	(18,391	)
Capital expenditures			(10,661	)			(6,736	)
Free cash flow		$	(28,271	)		$	(25,127	)

Reconciliation of Non-GAAP Financial Measures to Reported Operating Expenses

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Sales, general, and administrative		$	134,911			$	132,981
Reconciling items impacting sales, general, and administrative:
SeaSpine merger-related costs			(486	)			(757	)
Restructuring costs and impairments related to M6 product lines			187				(3,336	)
Strategic investments			(948	)			(1,547	)
Amortization/depreciation of acquired long-lived assets			—				(60	)
Litigation and investigation costs			(2,916	)			(3,042	)
Sales, general, and administrative expense, as adjusted		$	130,748			$	124,239
As a percentage of reported net sales			66.5	%			64.2	%
Sales, general, and administrative expense attributable to M6 product lines			(1,049	)			(2,388	)
Pro forma sales, general, and administrative expense, as adjusted		$	129,699			$	121,851
As a percentage of pro forma net sales			66.0	%			64.4	%

8

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Research and development expense, as reported		$	15,320			$	19,766
Reconciling items impacting research and development:
SeaSpine merger-related costs			(59	)			(116	)
Restructuring costs and impairments related to M6 product lines			—				(1,852	)
Strategic investments			(5	)			(1,983	)
Research and development expense, as adjusted		$	15,256			$	15,815
As a percentage of reported net sales			7.8	%			8.2	%
Research and development expense attributable to M6 product lines			(246	)			(1,192	)
Pro forma research and development expense, as adjusted		$	15,010			$	14,623
As a percentage of pro forma net sales			7.6	%			7.7	%

Reconciliations of Non-GAAP Financial Measures to Reported Non-Operating (Income) Expense

		Three Months Ended March 31,
(Unaudited, U.S. Dollars, in thousands)		2026				2025
Non-operating (income) expense		$	6,398			$	3,260
Reconciling items impacting non-operating expense:
Foreign exchange impact			(900	)			1,044
Interest and gain (loss) on investments			16				—
Employee retention credit			1,135				—
Non-operating expense, as adjusted		$	6,649			$	4,304
As a percentage of reported net sales			3.4	%			2.2	%
Losses (income) attributable to M6 product lines			138				(15	)
Pro forma non-operating expense, as adjusted		$	6,787			$	4,289
As a percentage of pro forma net sales			3.5	%			2.3	%

Source

Orthofix Medical Inc.

###

9

Drive Profitable Growth Investor Presentation May 2026

Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “positioned,” “deliver,” or “continue” or other comparable terminology. Forward-looking statements in this presentation include the Company's expectations regarding net sales, adjusted EBITDA, and free cash flow for the year ended December 31, 2026. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to successfully optimize our commercial channels, (vii) our success in defending legal proceedings brought against us, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. The Company undertakes no obligation to update, and expressly disclaims any duty to update, its forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law. The Company is unable to provide expectations of GAAP net income (loss), the closest comparable GAAP measures to adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions in this presentation. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP.

Non-GAAP Financial Measures Management uses certain non-GAAP financial measures in this presentation, most specifically Adjusted EBITDA, Adjusted Gross Margin, Adjusted Net Income and Free Cash Flow, as a supplement to GAAP financial measures to further evaluate the Company’s operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives. ​ Management believes it is important to provide investors with the same non-GAAP metrics it uses to evaluate the performance and underlying trends of the Company’s business operations to facilitate comparisons to its historical operating results and evaluate the effectiveness of its operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of the Company’s underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.​ Unless noted otherwise, full-year guidance is based on the current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. These non-GAAP financial measures should not be considered in isolation from, or as replacements for, the most directly comparable GAAP financial measures, as these measures are not prepared in accordance with U.S. GAAP.​ Reconciliations between GAAP and non‐GAAP results are included at the end of this presentation and represent the most comparable GAAP measure(s) to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s current report on Form 8-K regarding its first quarter 2026 press release filed on May 5, 2026 with the SEC and available on the SEC's website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com. The Company’s non-GAAP financial measures for the three months ended March 31, 2026, and 2025, have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6™ product lines. Accordingly, previously reported figures for 2025 have been recast to reflect the financial impact of this decision. Amounts may not add due to rounding.​ 3

Key Themes Disciplined, Profitable Growth to Maximize Value Creation Building on a strong foundation as a leading global med tech company with a comprehensive portfolio of spinal solutions, therapeutic solutions, biologics, specialized limb reconstruction solutions, and an advanced surgical navigation system (7D FLASH™) Driving meaningful and sustainable, above-market growth with broad, differentiated technologies, extensive commercial reach, and improving financial strength Delivering significant value to surgeons and patients and setting new standards of innovation through our products and extensive solutions Executing a clear strategy for profitable growth led by an established, world-class management team Advancing toward our 2028 financial targets to build on positive momentum, increase transparency, and maximize shareholder value creation 05 03 04 02 01

Commitment to Disciplined, Profitable Growth to Deliver Life-Changing Solutions and Maximize Value Creation Orthofix 5

Entering a New Phase in our Journey, Driven by Strategic, Operational and Financial Discipline Building on a Strong Foundation – Transformation Focused on Accelerating Excellence RECENT ACCOMPLISHMENTS AND TRANSFORMATIVE ACTIONS Building on clear competitive advantages Delivering consistent performance – achieved profitability objectives, adjusted EBITDA margin expansion Consistent free cash flow generation—$3.1 million1 in FY 2025 Supporting profitable growth with disciplined capital deployment Driving a culture of execution and accountability through established, world-class management team CONTINUED LEADERSHIP FOCUS AREAS –MULTIPLE LEVERS FOR PROFITABLE GROWTH Innovation FocusContinued development of differentiated products to meet diverse surgeon preferences Commercial Strategy EnhancementDeeper market penetration through comprehensive portfolio offerings Technology LeadershipHarnessing advanced systems for improved surgical outcomes and efficiency Growth SustainabilityEmphasis on high-quality revenue streams and operational excellence Cash Flow ManagementStrategic financial planning to achieve positive free cash flow 1 Excluding the free cash flow impact related to the Company's discontinuation of the M6 product lines and related restructuring activities.

Aligned Around Our Vision and Mission Vision The unrivaled partner in med tech, delivering exceptional experiences and life-changing solutions Mission We provide medical technologies that heal musculoskeletal pathologies. We enable our teams through opportunities for growth, ownership of responsibilities, and empowerment to execute. We do this for patients and the healthcare professionals who treat them. We collaborate with world-class surgeons and other partners to bring to market highly innovative, cost-effective, and user-friendly medical technologies through excellent customer service. We do this to improve people’s quality of life, and in doing so, create exceptional value for our customers, employees and stockholders.

Orthofix Today Healing Musculoskeletal Pathologies in Spine and Limb Reconstruction with Specialized Solutions and Enabling Technologies Attractive Stock Entry Point with Multiple Paths for Value Creation TTM Net Sales2 by Business ~$819.1M Therapeutic Solutions Spinal Implants, Biologics, and Enabling Technologies Limb Reconstruction ~17% Int’l HQLewisville, TX ~83% U.S. Founded 1980 Employees 1,600+ NASDAQ OFIX Office Manufacturing /Distribution 3rd-Party Logistics Global Presence TTM Net Sales2by Geography ~$475M Market-Cap1 ~$84.1M TTM Adjusted EBITDA2 ~71.7% TTM Adjusted Gross Margin2 ~$120.9M Cash, Cash Equivalents, and Restricted Cash2 Note: TTM = Trailing 12 Months. 1 4/30/2026. 2 As of 3/31/2026; All figures exclude impact of net sales and/or results of operations related to discontinuation of M6 product lines. Key Stats

Clear Strategic Pathway with Multiple Drivers for Value Creation Key Focus Areas & Priorities Innovate to drive growth and strengthen leading positions Future upside from high-impact new product launches Leverage technologies and sales channels across complementary product segments Create new entry points, cross-selling opportunities and stickier surgeon relationships Rigorous allocation of resources to high-return opportunities Focus on process and gross margin improvements Continuing to drive positive free cash flow in 2026 and thereafter Improved financial strength with profitability and term loan flexibility Invest in DifferentiatedTechnologies WhereOrthofix Can Win and Lead Capitalize on Multiple Access Points to Grow at Above-Market Rates Operate with Discipline for Margin Expansion Build Financial Resilience and Unlock Strong, Consistent Cash Flow Strategy is Driving Long-Term Profitable Growth and Positive Free Cash Flow

Two Growth Pillars – One Integrated Performance Engine Therapeutic Solutions (formerly Bone Growth Therapies) Combined portfolio with Biologics to target trauma surgeons Combine with select Limb Reconstruction products Expanding domestically through legacy SeaSpine distribution and U.S. Limb Reconstruction channels Biologics Expand cross-selling with U.S. Limb Reconstruction channels Spine Maximize procedural selling opportunity with Biologics, Limb Reconstruction, and Enabling Technologies Limb Reconstruction Maximize procedural selling opportunity with Biologics, Limb Reconstruction, and Enabling Technologies Enabling Technologies (ET) Focus on 7D equipment placements to drive recurring implant usage Leverage investment and drive synergistic approach across the portfolio

Comprehensive Portfolio of Transformative Solutions Improved Clinical Efficiencies and Economic Value with 7D Enabling Technology EstablishedDistribution Channels and Extensive Global Commercial Reach Large Addressable Markets with High-Growth Opportunities Across Continuum of Care World-Class, Visionary Leadership Team with Deep Sector Expertise Expanding and Deepening Customer Relationships 11 Capitalizing on Clear Competitive Advantages

Total Addressable Market 2026 – 2028 Expected Market Growth Rate Spinal Implants ~$10.1B ~3% – 4% Therapeutic Solutions (formerly Bone Growth Therapies) ~$0.6B ~2% – 3% Biologics ~$2.1B ~2% – 3% Limb Reconstruction (formerly Orthopedics) ~$2.6B ~5% – 6% Enabling Technologies ~$0.4B ~10% – 12% Addressable Markets ~$16B within Full Continuum of Care Well-Positioned for Favorable Macro Trends Aging Population Digital Healthcare AI and Machine Learning Enabling Technology Advancement Evolving Standards of Care

Spinal Implants Driving Innovation and Taking Share Select Product Examples Market Overview Sales channel optimization for growth, cross-selling, and OPEX leverage Pull through from lateral, cervical, and 7D earnouts Best-in-class implants to improve patient outcomes Interbody Cervical Thoracolumbar Fixation NorthStar™ OCT Mariner™ Deformity WaveForm™ (3D Printed) Explorer™ (Expandable) Reef™ (IBDs) ~$10.1BTAM1 Thoracolumbar Fixation Significant share capture opportunity ~3% – 4% market growth rate (2026 – 2028) Interbody Significant share capture opportunity ~3% – 4% market growth rate (2026 – 2028) Cervical Significant share capture opportunity ~3% – 4% market growth rate (2026 – 2028) OFIX Growth Drivers Shoreline™ ACS Wayfinder™ Phoenix™ MIS Meridian™ 1 U.S. Total Addressable Market. Sources: iData Research Inc.; U.S. Market Report for Spinal Implants and VCF; SmartTrak US Spine Market Report; Internal OFIX estimates Supporting Clinicians and Patients through Continuous Innovation of Procedure Solutions Comprehensive, best-in-class spinal implants designed to work in concert with 7D Navigation and biologics to support improved clinical outcomes Focus on deformity correction Proven expertise in cervical fixation and material science

AccelStim™ SpinalStim™ PhysioStim™ CervicalStim™ Complex Foot & Ankle Reconstruction and Fracture Management Therapeutic Solutions (formerly Bone Growth Therapies) Maximizing #1 Market Position Exceeding Market Growth Rate through Innovation and Expansion Safe, effective, non-surgical solution to promote bone healing in fracture management and high-risk spine fusions Most comprehensive portfolio of bone growth stimulation devices Most indications on the market to aid in bone healing solutions Select Product Examples #1 prescribed bone growth stimulator First to offer free recycling for patients to properly dispose of their devices PEMF technology approved since 1986 Prescribed devices 1,400,000+ Spine Fusion Therapy Market Overview Procedural selling focused on cross-selling with limb reconstruction and spine New market channels with established sales representatives AccelStim growth to penetrate Fracture market ~$0.6BTAM1 Spine #1 Position ~2% – 3% market growth rate (2026 – 2028) Fracture #2 Position ~2% – 3% market growth rate (2026 – 2028) OFIX Growth Drivers Note: PEMF = Pulsed Electromagnetic Field. 1 U.S. Total Addressable Market.

Biologics Renewed Focus on Advancing our Portfolio Strategically Introducing New Products to Capture Additional Market Share Full spectrum of biologic solutions to enhance fusion process and promote bone repair and growth Provide industry leading, best-in-class products in each of the major bone grafting categories Select Product Examples Demineralized Bone Matrix OsteoSurge™ 300 OsteoStrand™ Plus Synthetic Procedure-Specific OsteoCove™ OsteoBallast™ Market Overview Opportunities in current portfolio and spine Product innovation with clinical research Disc regeneration, channel expansion options ~$2.1BTAM1 Synthetic Significant share capture opportunity ~2% – 3% market growth rate (2026 – 2028) Cellular Allograft #2 Position ~2% – 3% market growth rate (2026 – 2028) OFIX Growth Drivers Trinity Elite™ Cellular Allograft Growth Factors, Other Do not participate 1 Global Total Addressable Market, including Growth Factors. Demineralized Bone Matrix #3 Position ~2% – 3% market growth rate (2026 – 2028)

Limb Reconstruction (formerly Orthopedics) Leading the Growth Unique portfolio of limb reconstruction solutions, addressing the most challenging orthopedic conditions in patients of all ages Proven Leader with Room to Grow through Innovation of Hardware and Digital Solutions Enabling Technologies - OrthoNext™ 1 Global Total Addressable Market. Sources: iData Research Inc. 2021; Berkyl Global Market Analysis 2020; SmartTrak 2024; Orthoworld Industry Annual Report, 2024; Acuity MD Data, 2025; Grandview Research, 2023; US Bone Transport Procedure Volume Analysis, 2015; CDC National Diabetes Statistics Report, 2022; Brownrigg, et al. Evidence-based Management of PAD & the Diabetic Foot, 2013. 45(6), 673-681; Behroozian et al. Art Thro Vasc Biology, 2020. 40(3). Select Product Examples Galaxy Gemini™ ComplexFracture Management Fitbone™ Limb Lengthening TL-HEX™ Extremity Deformity Correction TrueLok™ Elevate Market Overview Accelerating U.S. growth and expanding position Global sales channel optimization through execution and focused distribution New, unique product platforms with next-gen digital capabilities OFIX Growth Drivers ~$2.6BTAM1 Complex Fracture Management ~3% – 4% market growth rate (2026 – 2028) Limb Lengthening ~9% market growth rate (2026 – 2028) Limb Preservation ~5% market growth rate (2026-2028) Extremity Deformity Correction ~5% – 6% market growth rate (2026 – 2028) Limb Preservation *Significant share capture opportunity across all 4 pillars

Complex Fracture Management Limb Lengthening Limb Preservation Extremity Deformity Correction LIMB RECON Industry leader with a unique portfolio of limb reconstruction solutions, addressing the most challenging conditions in patients of all ages ENABLING TECHNOLOGIES ENABLING TECHNOLOGIES 17 Four Focus Areas – Limb Reconstruction

Tibial cortex transverse transport: Historical evolution, clinical applications, and future directions-Schroeder, et al. Foot & Ankle Surgery: Techniques, Reports & Cases, Vol 5, Issue 3, 100513 © 2025 The Author(s). Published by Elsevier Inc. on behalf of American College of Foot and Ankle Surgeons. Orthofix has not made any changes to the image above and use of this image is in no way an endorsement of the Journal or Authors Supporting surgeon-led correction of complex bony and soft-tissue defects Innovation Spotlight: TrueLok Elevate System The TrueLok Elevate device has not been approved by the FDA for treatment of ulcers and the safety and effectiveness of the TrueLok Elevate for treatment of ulcers has not been established. Minimally invasive, quick application, reproducible technique Versatile design Sterile, ready to use components 18

Patient Case Study – What Limb Reconstruction Means for Justin Background Justin, a 6'9" newlywed, suffered from severe genu valgum (knock‑knees) that caused chronic pain and limited mobility. As he prepared for fatherhood, he feared becoming disabled without corrective surgery. OFIX Unique Solution Under the care of Dr. William Terrell, the team elected to treat both legs simultaneously TL-HEX External Fixation System used on tibias for gradual, precise realignment Double ring configuration for added support due to height and size Post-surgery, fixators adjusted twice a day to correct the bone alignment Result / Outcomes Successful Orthofix-supported deformity correction procedure Restoration of patient mobility Strengthened customer loyalty Life is much better than it was before the surgery. I am almost back to 100% to what I should have been before. – Justin Click here for Justin’s story

Enabling Technologies Empowering Excellence with Real-Time, Integrated Smart Technologies Seizing Significant Opportunity to Leverage Technology and Expand Share in Spine FLASH™ Navigation with 7D Technology, world’s leading zero-radiation1 spine image-guided surgery system Allows surgeons to perform fast, cost-effective, and radiation-free surgery Pacesetting leader for open spine procedures and deformity correction Open and Percutaneous Spine Modules2 Market Overview OFIX Growth Drivers 7D deployments through commercial financing structures and product pull through Product integration with spinal implant portfolio Digital ecosystem expansion (pre-op planning, intra-op navigation, and post-op care) ~$0.4BTAM3 Spinal Navigation Significant share capture opportunity ~10% – 12% market growth rate (2026 – 2028) FLASH Navigation with 7D Technology Product Example Significant Focus in Spine 1 Based on a pre-op CT or MRI, no intra-op radiation is required using Open Spine Module, eliminating exposure to surgeons, staff, and patients. Intra-op radiation is required for Percutaneous Module. 2 ~40% of U.S. installed base has cranial module. 3 Global Total Addressable Market.

Innovation Spotlight – FLASH Navigation with 7D Technology Technology Differentiates Portfolio While Enabling Service to Full Continuum of Surgical Care 97.8% reduction in intraoperative radiation during adult degenerative spinal fusions1* Revolutionizing Spinal Navigation Created Meaningful Advantages with FLASH Navigation with 7D Technology 61% reduction in intraoperative radiation during complex pediatric deformity spinal fusions2* 98.8% accurate with no pedicle breach1* 94% faster than intraoperative CT-based systems3* 63.6 minutes saved per case4* Flexible Selling Models to Meet Unique Needs of Facility First and only image-guided surgery (IGS) system featuring 7D’s machine-vision technology, allowing surgeons to perform fast, cost-effective, radiation-free IGS Capital Purchase Lease “Earnout” through purchase of spine hardware and/or biologics; creating recurring revenue stream and stronger customer relationships Voyager Earnout Program *Not an Orthofix sponsored clinical study. 1 Malham GM, Munday NR. Comparison of novel machine vision spinal image guidance system with existing 3D fluoroscopy-based navigation system: a randomized prospective study. Spine J. 2022 Apr;22(4):561-569. doi: 10.1016/j.spinee.2021.10.002. Epub 2021 Oct 16. PMID: 34666179. 2 Comstock, Christopher P. MD; Wait, Eric MD. Novel Machine Vision Image Guidance System Significantly Reduces Procedural Time and Radiation Exposure Compared With 2-dimensional Fluoroscopy-based Guidance in Pediatric Deformity Surgery. Journal of Pediatric Orthopaedics ():10.1097/BPO.0000000000002377, March 6, 2023. | DOI: 10.1097/ BPO.0000000000002377 3 Jakubovic R, Guha D, Gupta S, et al. High speed, high density intraoperative 3D optical topographical imaging with efficient registration to MRI and CT for craniospinal surgical navigation. Sci Rep. 2018;8:14894. doi:10.1038/s41598-018-32424-z. 4 Lim KBL, Yeo ISX, Ng SWL, Pan WJ, Lee NKL. The machine-vision image guided surgery system reduces fluoroscopy time, ionizing radiation and intraoperative blood loss in posterior spinal fusion for scoliosis. Eur Spine J. 2023 Jul 10. doi: 10.1007/s00586-023-07848-5. Epub ahead of print. PMID: 37428212.Stewart G. Visible Light Navigation in Spine Surgery: My Experience With My First 150 Cases. Int J Spine Surg. 2022 Oct;16(S2):S28-S36. doi: 10.14444/8274. Epub 2022 Aug 5. PMID: 36456113; PMCID: PMC9808787.

Executing Through Transition – Guidance Reaffirmed Q1 2026 Results 22

Our first-quarter results reflect steady execution as we complete key spine commercial channel actions and sharpen our strategic focus. While the quarter continued to absorb the impact of these transitions, most notably in biologics, we saw improved commercial focus and operating discipline as the quarter progressed. Importantly, distributor transitions are now largely behind us, providing greater visibility for the remainder of the year. With recent spine leadership changes, a renewed focus on advancing our biologics portfolio, and planned product launches later this year, we believe Orthofix is positioned to deliver more consistent growth, expand margins, and generate strong free cash flow to support long‑term shareholder value. Massimo Calafiore President & Chief Executive Officer 23 1 The Company’s non-GAAP financial measures have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6 product lines. 2 Constant currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. 3 The reasons for and nature of non-GAAP disclosures by the Company, descriptions of the adjustments used to calculate those non-GAAP financial measures, and reconciliations of those non-GAAP financial measures to the most comparable GAAP financial measure(s), are provided in the Company’s press release issued, and Quarterly Report on Form 10-Q filed, on May 5, 2026.4 Spine Fixation is comprised of the Company's Spinal Implants product category, excluding motion preservation product offerings. Q1 2026 Financial Highlights $9.7M Non-GAAP Pro Forma Adjusted EBITDA1,3 Reflecting impacts from geography mix and commercial transitions $(28.3M) Free Cash Flow (FCF)3 FCF expected to be positive for full year, excluding potential legal settlements 6% Global Spine Fixation4 YoY Constant Currency Net Sales Growth U.S. Spine Fixation4 4% growth YoY; Steady execution following spine commercial channel actions 5% Therapeutic Solutions YoY Net Sales Growth Supported by disciplined commercial execution 70.7% Non-GAAP Pro Forma Adjusted Gross Margin1,3 40 basis point improvement over prior year   $196.4M Pro Forma Net Sales1 3% growth YoY on constant currency basis1,2 3% Global Limb Reconstruction YoY Constant Currency Net Sales Growth Reflecting continued demand for core fixation and reconstruction systems

24 Adjusted EBITDA reflects impacts from geography mix and commercial transitions – continuing to execute focused initiatives and margin-enhancement efforts Continued progress on global commercial launch of TrueLok™ Elevate System and preparing for full U.S. commercial launch of VIRATA™ Spinal Fixation System in 2H 2026 Continuing to execute the priorities outlined in long-term plan to transform our business and deliver on our commitment to drive disciplined, profitable growth Prudently deploying capital and prioritizing investment in profitable growth opportunities in areas where we can win Q1 2026 Key Messages 05 03 04 02 01 Steady execution following spine commercial channel actions that support a stronger, more scalable commercial organization to drive next phase of growth

Q1 2026 Results Summary First Quarter 2026 Results Summary (in millions)           Pro Forma Q1 2026   Pro Forma Q1 2025   Constant Currency Change Therapeutic Solutions $ 57.8 $ 55.1 4.9% Spinal Implants, Biologics, and Enabling Technologies 105.8 104.3 1.4% Global Spine 163.6 159.4 2.6% Global Limb Reconstruction 32.8 29.8 3.0% Pro forma net sales (excludes M6) $ 196.4 $ 189.2 2.7% Impact from discontinuation of M6 0.3 4.4 (94.5%) Reported net sales $ 196.7 $ 193.6 0.4% Non-GAAP Adjusted Gross Margin 70.7% 70.3% +~40 bps Non-GAAP Adjusted EBITDA $ 9.7   $ 11.4   (15.2%) Q1 Total Pro Forma Net Sales: $196.4M3% YoY pro forma, constant currency growth Q1 Non-GAAP Pro Forma Adjusted EBITDA: $9.7M 5% of pro forma net sales vs $11.4M in Q1 2025; 6% of pro forma net sales Q1 Non-GAAP Pro Forma Adjusted Gross Margin: 70.7% vs 70.3% of pro forma net sales in Q1 2025  Q1 Non-GAAP Pro Forma SG&A Expense: $129.7M 66% of pro forma net sales vs $121.9M in Q1 2025; 64% of pro forma net sales Q1 Non-GAAP Pro Forma R&D Expense: $15.0M 8% of pro forma net sales vs $14.6M in Q1 2025; 8% of pro forma net sales 25 Q1 2026 Total Pro Forma Net Sales $196.4M +2.7% YoY* Therapeutic Solutions $57.8M +4.9%* Global Limb Reconstruction $32.8M +3.0%* Global Spinal Implants, Biologics, & Enabling Technologies $105. 8M +1.4%* International Spinal Implants, Biologics & Enabling Technologies  $11.3M +4.1%* U.S. Spinal Implants, Biologics & Enabling Technologies  $94.5M +1.0% 89% 11% * YoY Growth is on a pro forma, constant currency basis compared to Q1 2025

SPINAL SOLUTIONS Global Spine Fixation net sales +6%* U.S. Spine Fixation net sales +4% Top 30 U.S. distributor partners grew net sales 27%* and 24% on TTM basis U.S. limited launch of VIRATA™ Spinal Fixation System ongoing THERAPEUTIC SOLUTIONS Net sales +5% Strong growth that benefited from cross-selling Continued focus on new surgeon adds and competitive surgeon conversions AccelStim™ Device continuing to drive fracture market growth Q1 2026 Business Segment Highlights 26 TTM = Trailing 12 Months * Net sales growth is on constant currency basis and compared to same prior-year quarter LIMB RECONSTRUCTION Global Limb Recon net sales +3%* Growth led by ongoing market release of TRUELOK™ Elevate System and FITBONE™ Bone Transport and Trochanteric Lengthening Nails

Full-Year 2026 Guidance1 $850M –$860M Net Sales $95M –$98M Adj. EBITDA Positive Free Cash Flowfor 2026² 1 As of the Company’s Q1 2026 Earnings Call hosted on 5/5/2026. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by Orthofix leadership as of any date other than 5/5/2026. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. 2 Excluding impact of any potential legal settlements, supported by margin improvement initiatives.

Uniquely Positioned to Accelerate Our Profitable Growth Engine Looking Forward 28

lp Looking Forward Accelerating Our Profitable Growth Engine Advancing Toward Our Goals for Consistent Above-Market Growth,Improved Profitability, and Positive Free Cash Flow Invest inDifferentiatedTechnologies in Areas Where We Can Win and Lead Innovation Capitalize on Multiple Access Points to Grow Business at Sustained, Above-Market Rates Operate with Discipline for Margin Expansion Build Financial Resilienceand Unlock Strong, Consistent Free Cash Flow 29

lp Investing in Differentiated Technologies Innovation Driving Growth and Strengthening Leading Market Positions Systematic Approach to Driving Innovation Rigorous allocation of resources to high-return opportunities Leverage technologies (7D, Biologics, Therapeutic Solutions) and sales channels (Spine, Limb Reconstruction) across complementary product segments Build enabling technology ecosystem using next-gen data, navigation and connected products for pre-, intra-, and post-op solutions Extensive expertise in intra-op surgical navigation creating accurate, efficient, and uninterrupted surgical workflow Continuum of musculoskeletal care integrated by Enabling Technologies Focal KPIs 1 Regular cadence of meaningful, high-impact new product launches 2 7% – 8% of salesinvested in R&D 3 Sustained sharecapture in U.S. Spine & U.S. Limb Reconstruction

On a Faster Path to Profitability with a Stronger Financial Profile Advancing Toward Our Long-Term Financial Goals 31

Operating with Discipline for Margin Expansion Well-Developed Infrastructure in Place to Further Scale and Support Growth Our Approach to Operational Excellence Building culture of excellence and accountability through implementation of the High Performance Management System (HPMS) Focusing on “Vital Few” initiatives to enhance operational excellence and drive business performance Key levers to drive higher margins and profitability across Company include: Rigorous allocation of resources to high-return opportunities Gross margin improvement Process improvements

Building Financial Resilience and Unlocking Strong, Consistent Free Cash Flow Strong Execution and Positive Free Cash Flow Momentum Driving Positive Free Cash Flow Expect to be free cash flow positive for full-year 20261 Drop-through to EBITDA from incremental revenue Working Capital improvements Efficient Working Capital Management Reduction in Inventory Days on Hand (DOH)and Instrument Efficiency Continued improvement in Days Sales Outstanding (DSO) 1 Excluding the impact of any potential legal settlements, supported by margin improvement initiatives. Near Breakeven For FY 2025

Strategy is Driving Long-Term Profitable Growth GrowthEngine Pillars Assumptions 6.5% – 7.5% Net Sales CAGR1 (2026 – 2028) Mid-Teens Adj. EBITDA (Full-year 2028) Positive Free Cash Flow Generation1 (2026 – 2028) Sustained market demand: weighted average market growth of ~4% to 5% Includes negative pricing impact of 1% to 2% No material change in reimbursement or regulatory environment ~300 bps of Gross Margin expansion over period Fixed cost leverage, moderating expense growth AI-informed enhancements to drive back-office efficiency Driven by continued Adj. EBITDA improvement Reduction in inventory DOH Improved instrument utilization DifferentiatedTechnologies Multiple Access Points MarginExpansion StrongCash Flow 2028 Financial Targets 1 Excluding impact of any potential legal settlements, supported by margin improvement initiatives.

Capital Allocation Priorities Investing to drive future profitable growth 1 Organic Growth Reinvest in business; enhance commercial channel; target capital spend levels at ~5% of sales 2 Inorganic Growth Tuck-in M&A to enhance growth & margin profile, support category leadership 3 Capital Structure Debt paydown and fortify balance sheet 4 Return of Capital In the absence of value-creating opportunities 35

World-Class Leadership Team with Extensive Med Tech Expertise – Focused on Results Combining Deep Institutional Knowledge with Fresh Perspectives and Proven Approaches Massimo Calafiore President and Chief Executive Officer Patrick Fisher President, Global Biologics and Limb Reconstruction Julie Andrews Chief Financial Officer Year Joined: 2024 Years in Industry: 20+ Year Joined: 2024 Years in Industry: 25+ Year Joined: 2024 Years in Industry: 25+ Aviva McPherron President, Global Operations & Quality Lucas Vitale Chief People & Business Operations Officer Beau StandishPhD, PEng Chief EnablingTechnologies Officer Year Joined: 2023 Years in Industry: 15+ Year Joined: 2024 Years in Industry: 10+ Year Joined: 2024 Years in Industry: 20+ Andrés Cedrón Chief Legal Officer Jill Mason Chief Compliance & Risk Officer Julie Dewey Chief Investor Relations & Communications Officer Year Joined: 2024 Years in Industry: 15+ Year Joined: 2024 Years in Industry: 25+ Year Joined: 2015 Years in Industry: 15+ Jason Shallenberger President,Therapeutic Solutions Year Joined: 2005 Years in Industry: 20+

Investment Summary Why Invest in Orthofix? 01 Strong fundamentals with profitable growth opportunity and compelling value proposition across diverse portfolio 02 More focused commercial strategy with robust innovation pipeline complemented by successful cross-selling 03 Established leadership team well-positioned to implement strategic vision and achieve sustainable, profitable growth across portfolio 04 Improved operational execution to drive toward profitability objectives and positive free cash flow 05 Long-term financial targets reflect confidence in sustainable growth trends, commercial strategy and execution

For additional information, please contact: Julie Dewey, IRC Chief IR & Communications Officer juliedewey@orthofix.com 209-613-6945 www.Orthofix.com NASDAQ: OFIX

Financial and Non-GAAP Reconciliation Tables Appendix 39

Net Sales by Major Product Category by Reporting Segment     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in millions)   2026     2025     Change     ConstantCurrencyChange   Therapeutic Solutions   $ 57.8     $ 55.1       4.9 %     4.9 % Spinal Implants, Biologics and Enabling Technologies*     105.8       104.3       1.4 %     1.4 % Global Spine*     163.6       159.4       2.6 %     2.6 % Global Limb Reconstruction     32.8       29.8       10.2 %     3.0 % Pro forma net sales*     196.4       189.2       3.8 %     2.7 % Impact from discontinuation of M6 product lines     0.3       4.4       (94.2 %)     (94.5 %) Reported net sales   $ 196.7     $ 193.6       1.6 %     0.4 % * Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.

Q1 2026 GAAP to Adj. EBITDA Bridge Reported Adjustments to U.S. GAAP Adjusted Q1 2026U.S. GAAP Results Foreign Exchange Impact Strategic Investments Impact of Discontinuation of M6 Product Lines SeaSpine Merger-Related Costs Acquisition-Related Fair Value Adjustments Amortization / Depreciation of Acquired Long-Lived Assets Interest & Gain/(Loss) on Investments Litigation and Investigation Costs Employee Retention Credit Share-based compensation expense and long-term incentive plan expense Long-TermTax Rate Adjustment Q1 2026Non-GAAP Results Net Sales $ 196.7 $ - $ - $ (0.3) $ - $ - $ - $ - $ - $ - $ -   $ 196.4 Cost of Sales 57.2 - (0.0) 0.4 0.5 - (0.2) - - - (0.3)   57.6 Gross Profit 139.5 - 0.0 (0.7) (0.5) - 0.2 - - - 0.3   138.8 Gross Margin 70.9%     70.7%         Sales, General, & Administrative 134.9 - (0.9) (0.9) (0.5) - - - (2.9) (0.0) -   129.7 Research & Development 15.3 - (0.0) (0.2) (0.0) - - - - - -   15.0 Acquisition-Related Amortization & Remeasurement 3.8 - - - - (0.8) (3.0) - - - -   - Share-based Compensation Non-GAAP Adjustment - - - - - - - - - - (6.3)   (6.3) Operating Income (Loss) (14.4) - 1.0 0.4 0.0 0.8 3.2 - 2.9 0.0 6.6   0.4 -7.3%     0.2%         Interest Income (Expense), Net (5.7) - - 0.0 - - - - - (0.2) -   (5.8) Other Income (Expense), Net (0.7) 0.9 - (0.1) - - - (0.0) - (1.0) -   (0.9)         Income (Loss) Before Tax (20.8) 0.9 1.0 0.3 0.0 0.8 3.2 (0.0) 2.9 (1.1) 6.6   (6.3) -10.6%     -3.2%         Income Tax Expense (Benefit) (0.1) - 0.0 (0.0) - - - - - - - 1.8 1.8 Effective Tax Rate -0.4%     28.0%         Net Income (Loss) $ (20.9) $ 0.9 $ 1.0 $ 0.3 $ 0.0 $ 0.8 $ 3.2 $ (0.0) $ 2.9 $ (1.1) $ 6.6 $ 1.8 $ (4.6) Net income (loss) as a percentage of net sales -10.6%     -2.3%         EBITDA $ (1.7) $ 0.9 $ 0.9 $ 0.3 $ (0.1) $ 0.8 $ - $ (0.0) $ 2.9 $ (1.0) $ 6.6 $ - $ 9.7 EBITDA as a percentage of net sales -0.9%     4.9%                          

Condensed Consolidated Balance Sheets (U.S. Dollars, in thousands, except par value data)   March 31,2026     December 31,2025       (Unaudited)         Assets             Current assets             Cash and cash equivalents   $ 120,278     $ 82,025   Restricted Cash     592       3,090   Accounts receivable, net of allowances of $8,990 and $8,308, respectively     137,775       135,746   Inventories     177,818       172,319   Prepaid expenses and other current assets     25,057       23,667   Total current assets     461,520       416,847   Property, plant, and equipment, net     125,327       129,399   Intangible assets, net     69,336       72,765   Goodwill     194,934       194,934   Other long-term assets     35,484       36,702   Total assets   $ 886,601     $ 850,647   Liabilities and shareholders’ equity             Current liabilities             Accounts payable   $ 54,686     $ 58,392   Current portion of finance lease liability     115       837   Other current liabilities     106,232       111,253   Total current liabilities     161,033       170,482   Long-term debt     221,335       157,391   Long-term portion of finance lease liability     12,937       17,060   Other long-term liabilities     56,110       55,677   Total liabilities     451,415       400,610   Contingencies             Shareholders’ equity             Common shares $0.10 par value; 100,000 shares authorized; 40,382 and 39,834 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively     4,038       3,983   Additional paid-in capital     820,247       813,769   Accumulated deficit     (389,241 )     (368,333 ) Accumulated other comprehensive income     142       618   Total shareholders’ equity     435,186       450,037   Total liabilities and shareholders’ equity   $ 886,601     $ 850,647  

Condensed Consolidated Statements of Operations     Three Months Ended       March 31,   (Unaudited, U.S. Dollars, in thousands, except share and per share data)   2026     2025   Net sales   $ 196,708     $ 193,646   Cost of sales     57,162       72,027   Gross profit     139,546       121,619   Sales, general, and administrative     134,911       132,981   Research and development     15,320       19,766   Acquisition-related amortization, impairment, and remeasurement     3,751       17,745   Operating loss     (14,436 )     (48,873 ) Interest expense, net     (5,664 )     (4,506 ) Other income (expense), net     (734 )     1,246   Loss before income taxes     (20,834 )     (52,133 ) Income tax expense     (74 )     (961 ) Net loss   $ (20,908 )   $ (53,094 )               Net loss per common share:             Basic   $ (0.52 )   $ (1.35 ) Diluted     (0.52 )     (1.35 ) Weighted average number of common shares (in millions):             Basic     40.4       39.2   Diluted     40.4       39.2  

Adjusted Gross Profit and Adjusted Gross Margin     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Gross profit   $ 139,546     $ 121,619   Share-based compensation and long-term incentive plan expense     331       461   SeaSpine merger-related costs     (528 )     600   Restructuring costs and impairments related to M6 product lines     (437 )     10,919   Strategic investments     —       13   Amortization/depreciation of acquired long-lived assets     177       313   Adjusted gross profit   $ 139,089     $ 133,925   Adjusted gross margin as a percentage of reported net sales     70.7 %     69.2 % Adjusted gross profit attributable to M6 product lines     (242 )     (906 ) Pro forma adjusted gross profit   $ 138,847     $ 133,019   Pro forma adjusted gross margin as a percentage of pro forma net sales     70.7 %     70.3 %

Adjusted EBITDA and Pro Forma Adjusted EBITDA     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Net loss   $ (20,908 )   $ (53,094 ) Income tax expense     74       961   Interest expense, net     5,664       4,506   Depreciation and amortization     13,493       34,431   Share-based compensation and long-term incentive plan expense     6,638       6,469   Foreign exchange impact     900       (1,044 ) SeaSpine merger-related costs     (69 )     1,130   Restructuring costs and impairments related to M6 product lines     (437 )     9,880   Strategic investments     950       3,514   Acquisition-related fair value adjustments     750       (610 ) Interest and (gain) loss on investments     (16 )     —   Litigation and investigation costs     2,916       3,042   Employee retention credit     (951 )     —   Adjusted EBITDA   $ 9,004     $ 9,185   Adjusted EBITDA as a percentage of reported net sales     4.6 %     4.7 % Operating losses attributable to M6 product lines     690       2,246   Pro forma adjusted EBITDA   $ 9,694     $ 11,431   Pro forma adjusted EBITDA as a percentage of pro forma net sales     4.9 %     6.0 %

Adjusted Net Income and Pro Forma Adjusted Net Income     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Net loss   $ (20,908 )   $ (53,094 ) Share-based compensation and long-term incentive plan expense     6,638       6,469   Foreign exchange impact     900       (1,044 ) SeaSpine merger-related costs     17       1,474   Restructuring costs and impairments related to M6 product lines     (624 )     30,204   Strategic investments     953       3,543   Acquisition-related fair value adjustments     750       (610 ) Amortization/depreciation of acquired long-lived assets     3,178       4,632   Litigation and investigation costs     2,916       3,042   Interest and (gain) loss on investments     (16 )     —   Employee retention credit     (1,135 )     —   Long-term income tax rate adjustment     2,106       2,200   Adjusted net loss   $ (5,225 )   $ (3,184 ) Operating losses attributable to M6 product lines     916       2,688   Long-term income tax rate adjustment for M6 product lines     (256 )     (753 ) Pro forma adjusted net loss   $ (4,565 )   $ (1,249 )

Cash Flow and Free Cash Flow     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Net cash used in operating activities   $ (17,610 )   $ (18,391 ) Net cash used in investing activities     (10,515 )     (6,736 ) Net cash provided by (used in) financing activities     63,970       (651 ) Effect of exchange rate changes on cash     (90 )     493   Net change in cash and cash equivalents   $ 35,755     $ (25,285 )     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Net cash used in operating activities   $ (17,610 )   $ (18,391 ) Capital expenditures     (10,661 )     (6,736 ) Free cash flow   $ (28,271 )   $ (25,127 )

Adjusted Sales, General and Administrative Expense     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Sales, general, and administrative   $ 134,911     $ 132,981   Reconciling items impacting sales, general, and administrative:             SeaSpine merger-related costs     (486 )     (757 ) Restructuring costs and impairments related to M6 product lines     187       (3,336 ) Strategic investments     (948 )     (1,547 ) Amortization/depreciation of acquired long-lived assets     —       (60 ) Litigation and investigation costs     (2,916 )     (3,042 ) Sales, general, and administrative expense, as adjusted   $ 130,748     $ 124,239   As a percentage of reported net sales     66.5 %     64.2 % Sales, general, and administrative expense attributable to M6 product lines     (1,049 )     (2,388 ) Pro forma sales, general, and administrative expense, as adjusted   $ 129,699     $ 121,851   As a percentage of pro forma net sales     66.0 %     64.4 %

Adjusted Research and Development Expense     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Research and development expense, as reported   $ 15,320     $ 19,766   Reconciling items impacting research and development:             SeaSpine merger-related costs     (59 )     (116 ) Restructuring costs and impairments related to M6 product lines     —       (1,852 ) Strategic investments     (5 )     (1,983 ) Research and development expense, as adjusted   $ 15,256     $ 15,815   As a percentage of reported net sales     7.8 %     8.2 % Research and development expense attributable to M6 product lines     (246 )     (1,192 ) Pro forma research and development expense, as adjusted   $ 15,010     $ 14,623   As a percentage of pro forma net sales     7.6 %     7.7 %

Adjusted Non-Operating (Income) Expense     Three Months Ended March 31,   (Unaudited, U.S. Dollars, in thousands)   2026     2025   Non-operating (income) expense   $ 6,398     $ 3,260   Reconciling items impacting non-operating expense:             Foreign exchange impact     (900 )     1,044   Interest and gain (loss) on investments     16       —   Employee retention credit     1,135       —   Non-operating expense, as adjusted   $ 6,649     $ 4,304   As a percentage of reported net sales     3.4 %     2.2 % Losses (income) attributable to M6 product lines     138       (15 ) Pro forma non-operating expense, as adjusted   $ 6,787     $ 4,289   As a percentage of pro forma net sales     3.5 %     2.3 %

FAQ

How did Orthofix (OFIX) perform financially in Q1 2026?

Orthofix reported Q1 2026 net sales of $196.7 million, up 1.6% year over year. Non-GAAP pro forma net sales were $196.4 million, up 2.7% on a constant currency basis, while the GAAP net loss narrowed to $20.9 million from $53.1 million.

What were Orthofix (OFIX) segment growth trends in Q1 2026?

In Q1 2026, Global Spine Fixation net sales grew 6% year over year on a constant currency basis. Therapeutic Solutions net sales increased 5%, and Global Limb Reconstruction net sales rose 3%, highlighting broad-based though moderate growth across Orthofix’s major businesses.

Did Orthofix (OFIX) improve profitability in Q1 2026?

Orthofix’s GAAP net loss improved to $20.9 million, or $(0.52) per share, versus $(53.1) million, or $(1.35) per share, a year earlier. However, non-GAAP pro forma adjusted EBITDA declined to $9.7 million from $11.4 million, and the pro forma adjusted EBITDA margin fell from 6.0% to 4.9%.

What is Orthofix’s (OFIX) full-year 2026 financial guidance?

For 2026, Orthofix expects net sales of $850–$860 million, implying about 5.5% pro forma constant currency growth at the midpoint. It also projects non-GAAP adjusted EBITDA of $95–$98 million and positive free cash flow for 2026, excluding any potential legal settlements.

How strong is Orthofix’s (OFIX) balance sheet after Q1 2026?

As of March 31, 2026, Orthofix held $120.9 million in cash, cash equivalents, and restricted cash, up from $85.1 million at year-end. Total assets reached $886.6 million, with shareholders’ equity of $435.2 million and long-term debt of $221.3 million.

What non-GAAP metrics does Orthofix (OFIX) emphasize in its Q1 2026 results?

Orthofix highlights non-GAAP pro forma adjusted gross margin of 70.7%, slightly above 70.3% a year earlier, and non-GAAP pro forma adjusted EBITDA of $9.7 million. It also reports free cash flow of negative $28.3 million, defined as operating cash flow minus capital expenditures.

Filing Exhibits & Attachments

3 documents

Press Releases

• EX-99.1 EX-99.1 643.1 KB
• EX-99.2 EX-99.2 68.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB